GRM1 and schizophrenia: If mGlu1 PAMs can reverse deficits in mPFC inhibitory transmission, these combined actions could be an alternative approach to reduce positive symptoms and treat cognitive deficits in patients with schizophrenia, providing an exciting improvement over existing antipsychotics.